Darwin AG, now operating as Novogenia AG (ISIN DE000A3C35W0), has completed its name change following the registration of the corresponding amendment to the Articles of Association in the Commercial Register. The change, approved at the Annual General Meeting on June 26, 2026, aligns the company’s legal name with its core operating brand, Novogenia GmbH, which has been the primary driver of the group’s business and growth in the field of human genetics.
The renaming is part of a strategic effort to simplify the corporate structure, create a consistent image across all target groups, and support clearer positioning toward customers, partners, investors, and the capital market. Novogenia GmbH, a wholly owned subsidiary, has been active in human genetics for years, developing and selling personalized products based on genetic analysis. The Novogenia brand is recognized for its scientific expertise and technological innovation.
“Novogenia has been at the heart of our operational business and our international market presence for many years. By operating under the name Novogenia AG, we are consistently unifying our corporate and brand identities. This enhances the visibility and recognition of our Group while reinforcing our ambition to establish Novogenia as a leading international provider of personalized healthcare and longevity solutions, as well as a strong and recognizable brand in the capital market,” said Dr. Daniel Wallerstorfer, CEO of Novogenia AG.
The name change does not affect the company’s strategic direction, business model, or operational activities. The stock market listing and existing shareholder rights remain unchanged. The Novogenia Group, headquartered in Munich, Germany, is a European healthcare company specializing in human genetics and personalized products. Its genetic analyses, conducted in its own laboratory, are used in diagnosis, treatment, and prevention of diseases, as well as in producing tailored nutritional supplements and cosmetics. The company also partners with physicians, therapists, pharmacists, nutritionists, and fitness trainers to optimize patient care based on genetic predispositions. Additionally, Novogenia holds investments in innovative biotech, healthcare, and life sciences companies.
For more information, visit https://novogenia.com/novogenia-ag.
